drugset / Trial / NCT07226362

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

NCT07226362

Phase 1 Completed 44 enrolled Aspeya Switzerland SA
RandomizedCrossoverOpen-labelBasic science

Summary

A Phase 1 clinical trial to evaluate the pharmacokinetics, relative bioavailability, safety and tolerability of DHE inhalation powder delivered by dry powder inhaler, DHE IV, and DHE nasal spray.

Timeline

Start
2025-06-09
Primary completion
2025-10-02
Completion
2025-10-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dihydroergotamine Small molecule 1 mg Inhaled
Comparator Dihydroergotamine Small molecule 2 mg Inhaled
Comparator Metoclopramide Small molecule 10 mg Intravenous

Indications

No indication recorded.